Tokyo, May 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061498) titled 'The effect of letrozole co-administration with follitropin delta on unexpected poor ovarian response and embryological/reproductive outcomes in high-AMH patients: a retrospective cohort study' on May 8.
Study Type:
Observational
Primary Sponsor:
Institute - Haruki Ladies Clinic
Condition:
Condition - infertility
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Does letrozole co-administration with follitropin delta reduce poor ovarian response and improve embryological outcomes in high-AMH patients, and is basal FSH an independent predictor of poor ovarian response in this population?
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 25
years-old
=
Gender - Female
Key inclusion criteria - All patients who underwent follitropin delta GnRH antagonist stimulation cycles between November 2021 and April 2026
Key exclusion criteria - (i) oocyte retrieval was not performed due to complete ovulation prior to retrieval; (ii) transvaginal oocyte retrieval was not possible due to uterine fibroids causing inaccessibility of the ovary; or (iii) excessive oocyte retrieval with ovarian hyperstimulation requiring cycle cancellation. Patients with antiphospholipid syndrome or systemic lupus erythematosus were retained in the stimulation and embryological analyses but excluded from pregnancy outcome analyses
Target Size - 600
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 05 Month 08 Day
Date of IRB - 2025 Year 05 Month 08 Day
Anticipated trial start date - 2025 Year 05 Month 08 Day
Last follow-up date - 2025 Year 05 Month 08 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070246
Disclaimer: Curated by HT Syndication.
